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Summary Twenty patients with epithelial ovarian carcinoma were treated with high-dose cisplatin
200mg m-2 Patients were to receive three cycles at 21 day intervals. Treatment was stopped if severe
myelosuppression or any neurotoxicity occurred. Overall, eight (40%) of patients responded with a complete
response in five (25%). Four of 16 (25%) previously treated patients responded. The median duration of
response was 44 weeks (range 6-130). In patients previously treated there was a significant association
(P<0.002) between response and a remission free interval of 52 weeks or more from primary chemotherapy.
Toxicity was assessable in 18 patients. Alopecia and nausea/vomiting were common. Myelosuppression was
recorded in nine patients delaying planned administration in eight of 35 cycles. Five patients developed
anaemia and six thrombocytopenia. Neurotoxicity affected seven patients and varying degrees of tinnitus six
patients. Neurotoxicity and myelosuppression were indications for cessation of treatment in 8 patients
receiving less than three cycles. Analysis revealed no significant association between toxicity and prior cisplatin
exposure, age or the amount of high-dose cisplatin administered. This series reveals that it is possible to
achieve good response rates using high-dose cisplatin without encountering debilitating neurotoxicity.
Most patients with epithelial ovarian carcinoma (EOC) pres-
ent with advanced disease making complete resection of
tumour impossible in many cases (Katz et al., 1981). As the
tumour is relatively chemosensitive, chemotherapy is impor-
tant post-operative management. Clinical response rates of
over 60% have been reported with single agent cisplatin first
line therapy (Lambert & Berry, 1985). The majority of
patients, however, will relapse and subsequent responses
appear dependent upon the duration of primary remission
(Markman et al., 1991).
High-dose cisplatin (200 mg m2) is effective as first and
second line therapy in ovarian cancer (Hainsworth et al.,
1990; Ozols et al., 1985). The rationale for dose
intensification results from the steep dose-response relation-
ship in cisplatin sensitive cell lines (Behrens et al., 1985). The
major dose limiting problem of nephrotoxicity is overcome
by hypertonic saline and vigorous chloruresis (Ozols et al.,
1984) but myelosuppression and in particular, neurotoxicity,
remain problematic.
This study was undertaken to evaluate the response
associated with single agent high-dose cisplatin therapy in
patients with EOC (untreated or relapsed) but with cessation
of treatment if any neurotoxicity or severe myelosuppression
occurred.
Patients and methods
Twenty patients with histologically proven EOC were entered
into the study. Their characteristics are shown in Table I. In
all cases there were no medical contra-indications to treat-
ment. Patients had measurable and/or evaluable disease, an
ECOG performance score of 0-2 and a life expectancy of
greater than 3 months. Baseline creatinine clearance was
greater than 50 ml min '. Patients with a previous history of
malignancy (except non-melanomatous skin cancer) or any
degree of neurotoxicity from prior cisplatinum therapy were
excluded. Sixteen patients had prior treatment with a variety
of agents (Table I).
Previous treatment
No previously treated patient had progressed on primary
therapy. The median interval from primary surgery to going
on-study was 52 weeks (range 2-200).
A high-dose cisplatin regimen (200 mgm2) was admin-
istered as described by Ozols (Ozols et al., 1985). The inten-
tion was to give a maximum of three cycles of treatment at
three weekly intervals. Patients were withdrawn from the
study if there was progression of disease, absence of
evaluable response after two cycles or severe toxicity. Treat-
ment was delayed if there was significant myelosuppression
(WCC <3.0; platelets < 100,000) or impared renal function
(creatinine clearance <50 ml min- ). Patients were with-
drawn if severe myelosuppression occurred. A careful history
and clinical examination was undertaken at each visit, in
particular to detect cisplatin neurotoxicity (i.e. peripheral
neuropathy, ototoxicity, visual impairment and gait distur-
bance). Any evidence of neurotoxicity whether objective or
subjective resulted in withdrawal from study. The antiemetic
Table I Patient characteristics
Characteristic No. ofpatients
Total 20
Age 26-76 yrs, median = 51
Histology
Serous 10
Mucinous 3
Endometrioid 3
Adenocarcinoma 4
Differentiation
Well 4
Moderate 9
Poor 6
NK 1
Previous Treatment
Cisplatin/Cyclophosphamide 5
PAB/Escalating Cyclophosphamide 4
Cisplatin/Mitoxantrone 2
Chlorambucil 2
Carboplatin 2
Treosulphan I
No Previous Tx. 4
Evaluable Disease
Pelvic mass 16
Abdominal mass 3
Liver metasteses 1
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regime utilised consisted of metoclopramide 2 mg kg-' and
dexametasone 8 mg prior to each bag of cisplatin. From Day
3-5, if nausea and vomiting was still troublesome an intra-
venous infusion of Metoclopramide 250 mg and Dex-
ametasone 4 mg QDS was given. On discharge all patients
were given Dexametasone 4 mg QDS and Prochlorperazine
10mg QDS for 3 days.
Responses were assessed using International Union
Against Cancer criteria (UICC, 1987). All partial and com-
plete responses were confirmed on CT scan. Acute toxicity
was evalued using WHO criteria (Miller et al., 1981).
Statistical methods
All statistical analysis were performed using Chi2 with Yates
correction or Fisher's exact test.
Results
Response
A total of 20 patients were recruited. Eighteen patients were
evaluable for response as two patients died following their
first course of treatment, one from a ruptured duodenal
artery and the second myocardial infarction. Post-mortem
was not performed in the latter case. Overall, eight (40%)
patients responded (95% confidence limits 19-61%),five of
whom achieved a complete response (CR). Two patients had
stable and eight progressive disease, six of whom received
only one course of treatment. All previously untreated
patients had a complete clinical response. In previously
treated patients the response rate was 25% (95% confidence
limits 15-36%). The median duration of response was 44
weeks (range 6-130). In the previously untreated group, 3
had not received platinum and two of these patients failed to
respond (Table II). Of 13 patients who had prior exposure to
platin containing regimens, those with CR initially but
relapse within 9 months did not respond to high-dose
therapy, whereas two of five with a disease free interval
beyond 9 months responded. One patient with static disease
following primary platin, achieved a partial response with
high-dose therapy (Table III). In previously treated patients,
there was no significant association between response and the
duration from primary surgery, age or the amount of prior
cisplatinum exposure. A significant (P<0.002) association
was noted between response and remission period of greater
than 52 weeks from first line therapy.
Toxicity
Toxicity is summarized in Table IV. This was assessed in 18
patients evaluable for response. Myelosuppression occurred
in nine patients four of whom developed grade 3/4 sepsis. A
total of 35 cycles of treatment were administered with delay
in eight (23%) due to myelosuppression. Anaemia occurred
in five patients necessitating blood transfusion in four (mean
of three units). Thrombocytopenia was recorded in six
patients, three were given platelet transfusions (mean of 11
units), with one patient presenting with epistaxis. Nausea and
vomiting were common with only two patients unaffected.
Alopecia affected all but one patient in varying degrees.
Neurotoxicity affected seven patients and ototoxicity six. One
patient complained of hearing loss and the remainder tin-
Table III Response and previous platin exposure n = 13
Response toplatin Response to high-dose
5 pts. CR<9 months duration 5 NR
5 pts. CR>9 months duration 1 CR, IPR
2 Static, 1 early death
1 pt. PR 1 NR
2 pts. Static disease<6 months 1 PR, 1 NR.
Table IV Toxicity (WHO grade) n = 18
Toxicity 0 1 2 3 4
Nausea/Vomiting 2 7 6 3 0
Alopecia 1 5 5 7 0
Leukopenia 9 0 2 3 4
Anaemia 13 0 4 1 0
Thrombocytopenia 12 0 0 4 2
Sepsis 11 3 0 2 2
Peripheral neuropathy 11 3 4 0 0
Tinnitus 6
Transfusions
Blood 4 pts.
Platelets 3 pts.
nitus. Audiometric studies in four of these patients revealed
high tone deafness and was not performed in the other two.
Peripheral neuropathy and tinnitus were transient in all but
one patient and resolved within a 14 month period from end
of treatment. Long term sequelae was recorded in one patient
where hearing loss persisted in one ear requiring the use of
an aid. The median follow-up time for those with neuro/
ototoxicity was 14 months (range 6-40 months). Neurotox-
icity and sepsis were the main indications for cessation of
therapy in eight patients receiving less than three cycles.
Analysis of patients revealed no significant association with
toxicity and previous dose exposure to cisplatin, age and time
from primary surgery or present dose of high-dose cisplatin.
Discussion
The problems of nausea, vomiting and nephrotoxicity
associated with high-dose cisplatin therapy have been
ameliorated with antiemetics and vigourous hydration.
Although myelosuppression can occur, neurotoxicity is now
considered the dose limiting factor with high-dose cisplatin,
which can progress even after cessation of treatment
(Grunberg et al., 1989; Pollera et al., 1988). Ozols et al.
(1985) achieved a response rate of 32% in 19 patients with
relapsed ovarian carcinoma, but reported gait disturbance in
37% of patients with 2/19 becoming wheelchair dependent.
Similarly, Pancini et al. (1987) reported gait disturbance in
three of 18 patients with a high incidence of peripheral
neuropathy (13/16) in those who received more than two
cycles of high-dose cisplatin. We have demonstrated a similar
response rate to other studies, without severe debilitating
neurotoxicity. In our series, though neurological deficits
occurred, they resolved within a 14 month period following
treatment in all except one patient with persistent hearing
loss in one ear.
Table II Response with respect to previous treatment n = 20
Previous treatment
Response None Platin regime Other (non platin) Overall
Complete 4 1 0 5
Partial 0 2 1 3
Static disease 0 2 0 2
Disease progression
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There would seem little doubt that high-dose cisplatin is
effective in the treatment of ovarian cancer, but this must be
balanced against its side effects. The inability to predict those
who will develop neuro or ototoxicity is a continuing con-
cern, and analysis of this series has been non contributory in
this respect. There is however, clear evidence from other
studies which show that neurological sequelae are dose
dependent (Ozols et al., 1985, 1984; Grunberg et al., 1989;
Pollara et al., 1988). Until the efficacy of possible neuro-
protectors such as WR-2721 (Mollman et al., 1988) have
been confirmed, dose intensification with cisplatin will con-
tinue to be limited by neurotoxicity. Nevertheless our series
shows that dose intensification can be employed without
resultant debilitating neurotoxicity, and yet achieve similar
responses to that reported in other series.
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